- Home
- BCSF vs HQL Comparison
BCSF vs HQL Comparison
Compare BCSF & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BCSF | HQL |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Investment Managers |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.7M | 689.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCSF | HQL |
|---|---|---|
| Price | $11.09 | $18.17 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $12.63 | N/A |
| AVG Volume (30 Days) | ★ 474.3K | 114.6K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | ★ 17.12% | 11.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.27 | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.76 | ★ $24.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.95 | $15.60 |
| 52 Week High | $14.70 | $22.67 |
Technical Indicators
Market Signals| Indicator | BCSF | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 34.00 |
| Support Level | N/A | $16.06 |
| Resistance Level | $13.74 | $20.20 |
| Average True Range (ATR) | 0.20 | 0.48 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 16.28 | 16.47 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.